List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4865751/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Two Patients with Reversible Cerebral Vasoconstriction after Carotid Artery Stenting. Journal of Neuroendovascular Therapy, 2022, 16, 106-115.	0.1	2
2	Transarterial embolization for falx dural arteriovenous fistula through the artery of Davidoff and Schechter: A case report. Radiology Case Reports, 2022, 17, 700-705.	0.6	1
3	Evaluation of association between parameters related to penetration into cerebrospinal fluid and the microbiological efficacy of vancomycin in patients with bacterial meningitis. Journal of Chemotherapy, 2022, 34, 157-165.	1.5	0
4	Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial. JMIR Research Protocols, 2022, 11, e37898.	1.0	3
5	Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. Esophagus, 2022, 19, 617-625.	1.9	1
6	CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 1239-1254.	4.2	15
7	Mechanical Thrombectomy for Acute Ischemic Stroke Complicated by Bacterial Meningitis and Infective Endocarditis. Journal of Neuroendovascular Therapy, 2021, 15, 175-180.	0.1	0
8	Correlation between Higher Brain Dysfunction and Cerebral Blood Flow after Carotid Artery Stenting. Journal of Neuroendovascular Therapy, 2021, , .	0.1	0
9	Two cases of symptomatic secondary hypophysitis due to Rathke's cleft cysts treated with glucocorticoids: long-term follow-up. Endocrine Journal, 2021, 68, 269-279.	1.6	2
10	Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. PLoS ONE, 2021, 16, e0251272.	2.5	7
11	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5.5	13
12	Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Scientific Reports, 2021, 11, 13450.	3.3	14
13	ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review. AACE Clinical Case Reports, 2021, 7, 249-255.	1.1	1
14	Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction. BMC Neurology, 2021, 21, 274.	1.8	4
15	Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. Frontiers in Oncology, 2021, 11, 708039.	2.8	14
16	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. International Journal of Clinical Oncology, 2021, 26, 2205-2215.	2.2	6
17	Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction. Scientific Reports, 2021, 11, 21772.	3.3	11
18	Serum antiâ€LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16

#	Article	IF	CITATIONS
19	Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon, 2020, 6, e04661.	3.2	16
20	Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Diagnostics, 2020, 10, 71.	2.6	7
21	White matter dissection and structural connectivity of the human vertical occipital fasciculus to link vision-associated brain cortex. Scientific Reports, 2020, 10, 820.	3.3	30
22	miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS ONE, 2020, 15, e0229577.	2.5	16
23	GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Scientific Reports, 2020, 10, 8435.	3.3	9
24	Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. International Journal of Molecular Medicine, 2020, 46, 1274-1288.	4.0	11
25	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Scientific Reports, 2019, 9, 10004.	3.3	24
26	Transclival clipping for giant vertebral artery aneurysm: A case report. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2019, 17, 107-112.	0.3	0
27	Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model. Oncotarget, 2019, 10, 175-183.	1.8	24
28	Eighty percent survival rate at 15Âyears for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. Journal of Neuro-Oncology, 2019, 141, 205-211.	2.9	17
29	MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS ONE, 2019, 14, e0210400.	2.5	23
30	Effects of bilateral pallidal deep brain stimulation on chorea after pulmonary thromboendarterectomy with deep hypothermia and circulatory arrest: a case report. Acta Neurochirurgica, 2018, 160, 393-395.	1.7	8
31	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. World Neurosurgery, 2018, 112, e69-e73.	1.3	26
32	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38
33	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. Oncotarget, 2018, 9, 27471-27486.	1.8	30
34	Semi-quantitative Assessment Using [¹⁸ F]FDG Tracer in Patients with Severe Brain Injury. Journal of Visualized Experiments, 2018, , .	0.3	5
35	Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. Oncotarget, 2018, 9, 8836-8848.	1.8	18
36	Plasticity in Glioma Stem Cell Phenotype and Its Therapeutic Implication. Neurologia Medico-Chirurgica, 2018, 58, 61-70.	2.2	25

#	Article	IF	CITATIONS
37	Elevation of Autoantibody in Patients with Ischemic Stroke. Neurologia Medico-Chirurgica, 2018, 58, 303-310.	2.2	12
38	Image feature conversion of pathological image for registration with ultrasonic image. , 2018, , .		1
39	Cerebellar hemorrhage due to dural arteriovenous fistula mimicking a hemorrhagic metastatic brain tumor: a case report. Nosotchu, 2018, 40, 427-431.	0.1	0
40	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666.		26
41	Transforming growth factor-Î ² and stem cell markers are highly expressed around necrotic areas in glioblastoma. Journal of Neuro-Oncology, 2016, 129, 101-107.	2.9	32
42	Intrinsic protective mechanisms of the neuron-glia network against glioma invasion. Journal of Clinical Neuroscience, 2016, 26, 19-25.	1.5	18
43	Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters, 2016, 11, 1615-1620.	1.8	207
44	Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4112-4112.	1.4	2
45	Liposomally formulated phospholipid-conjugated indocyanine green for intra-operative brain tumor detection and resection. International Journal of Pharmaceutics, 2015, 496, 401-406.	5.2	23
46	Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX). Journal of Translational Medicine, 2015, 13, 71.	4.4	35
47	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	2.3	28
48	IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Journal of Neuro-Oncology, 2015, 124, 493-500.	2.9	9
49	Genetic Basis of Primary Central Nervous System Lymphoma. Blood, 2015, 126, 2687-2687.	1.4	1
50	Direct application of MALDI-TOF mass spectrometry to cerebrospinal fluid for rapid pathogen identification in a patient with bacterial meningitis. Clinica Chimica Acta, 2014, 435, 59-61.	1.1	78
51	Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. Journal of Neuro-Oncology, 2014, 117, 261-268.	2.9	12
52	Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas. BMC Cancer, 2014, 14, 452.	2.6	24
53	Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma. Clinical Cancer Research, 2012, 18, 5672-5681. 	7.0	35
54	Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas. Journal of Experimental and Clinical Cancer Research, 2012, 31, 85.	8.6	27

#	Article	IF	CITATIONS
55	Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. Journal of Neuro-Oncology, 2011, 102, 443-449.	2.9	23
56	Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy. Anticancer Research, 2011, 31, 4475-9.	1.1	11
57	Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma. Acta Neurochirurgica, 2009, 151, 263-268.	1.7	7
58	Clinical Proteomics in Cancer Research – Promises and Limitations of Current Two-Dimensional Gel Electrophoresis. Current Medicinal Chemistry, 2008, 15, 2393-2400.	2.4	24
59	High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Research, 2008, 28, 415-8.	1.1	26
60	Primary diffuse leptomeningeal gliomatosis followed with serial magnetic resonance images. Neuropathology, 2007, 27, 290-294.	1.2	12
61	Results of Gamma Knife Surgery alone for Brain Metastases : Indications for and Limitations of Local Treatment Protocol without Prophylactic Whole Brain Radiation Therapy(<special issue=""> Current) Tj ETQq1 1</special>	0.7 6.4 314	rg&T /Overlo
62	Gamma Knife Surgery Alone for Less Than 5 Brain Metastases : Is Prophylactic Whole Brain Radiation Therapy Necessary?. Japanese Journal of Neurosurgery, 2007, 16, 497-502.	0.0	0
63	Cathepsin D Is a Potential Serum Marker for Poor Prognosis in Glioma Patients. Cancer Research, 2005, 65, 5190-5194.	0.9	104
64	Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats. Clinical Cancer Research, 2005, 11, 3821-3827.	7.0	38
65	Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. International Journal of Oncology, 2005, 26, 993-8.	3.3	8
66	Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology, 2004, 63, 2384-2386.	1.1	30
67	Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis. Cancer Research, 2004, 64, 2496-2501.	0.9	156
68	Whole-brain radiation therapy is not beneficial as an adjuvant therapy for brain metastases compared with localized irradiation. Anticancer Research, 2002, 22, 325-30.	1.1	5
69	Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis. International Journal of Molecular Medicine, 2002, 10, 187-92.	4.0	12
70	Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors. Cancer Gene Therapy, 2000, 7, 1263-1269.	4.6	10